NUCB1 and breast cancer: SHON-Nuc+ in the whole NUH-ES-BC cohort was associated with prolonged BCSS and a reduced risk of death from BC [HR (95% CI) = 0.66 (0.55–0.80), p < 0.0001] (Fig. 2a), in the low risk patients [NPI < 3.4; HR (95% CI) = 0.53 (0.32–0.88), p = 0.015] (Fig. 2b), and in the ERα+ subgroup [HR (95% CI) = 0.61 (0.48-0.76), p < 0.0001] (Fig. 2c).